VOR BIOPHARMA INC

RA Capital’s 2.1 M‑share buy at VOR BioPharma signals confidence in its cell‑therapy pipeline amid volatile pricing, offering investors a fresh liquidity boost and a potential long‑term upside.

RA Capital’s strategic Vor BioPharma buy signals confidence as telitacicept receives Chinese approvals—could spark price momentum.

TCG Crossover GP II keeps a steady 2.84 m‑share stake in Vor BioPharma, underscoring long‑term confidence in its cell‑therapy pipeline amid market swings and a negative P/E.

Investor insights on Vor BioPharma: TCG Crossover’s steady 2.84M shares, active insider buying/selling, and Phase‑III trial risks—all key for pricing outlook.